Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
granzyme-B targeted [64Cu]-labeled PET radiotracer
- Development stage
- Phase 1
- Lead developer
- Ratio Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
A granzyme-B targeted [64Cu]-labeled PET radiotracer is a diagnostic imaging agent developed by Ratio Therapeutics (specifically candidates RTX-4001 and RTX-4002) designed to visualize immune cell activity. The tracer targets Granzyme B (GzmB), a serine protease released by activated cytotoxic T lymphocytes and natural killer (NK) cells to induce apoptosis in target cells. By binding to GzmB, the tracer allows for the non-invasive assessment of the immune response within the tumor microenvironment using Positron Emission Tomography (PET). The use of the Copper-64 (64Cu) isotope provides a half-life suitable for imaging biological processes over several hours, potentially serving as a predictive biomarker for response to cancer immunotherapies such as checkpoint inhibitors.
- Other names
- 64Cu-GzmB-PETCopper-64 labeled granzyme B tracerCopper64 labeled granzyme B tracerCopper 64 labeled granzyme B tracerGranzyme-B targeted [Cu-64]-labeled PET radiotracer
02
Targets
GZMB (Granzyme B)
Beyond the preview
Go deeper on granzyme-B targeted [64Cu]-labeled PET radiotracer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on granzyme-B targeted [64Cu]-labeled PET radiotracer.